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The RV144 HIV-1 trial of the canary pox vector
(ALVAC-HIV) plus the gp120 AIDSVAX B/E vaccine
demonstrated an estimated efficacy of 31%, which
correlated directly with antibodies to HIV-1 envelope
variable regions 1 and 2 (V1-V2). Genetic analysis of
trial viruses revealed increased vaccine efficacy
against viruses matching the vaccine strain at V2
residue 169. Here, we isolated four V2 monoclonal
antibodies from RV144 vaccinees that recognize
residue 169, neutralize laboratory-adapted HIV-1,
and mediate killing of field-isolate HIV-1-infected
CD4+ T cells. Crystal structures of two of the V2 anti-
bodies demonstrated that residue 169 can exist
within divergent helical and loop conformations,
which contrasted dramatically with the b strand
conformation previously observed with a broadly
neutralizing antibody PG9. Thus, RV144 vaccine-
induced immune pressure appears to target a region
that may be both sequence variable and structurally
polymorphic. Variation may signal sites of HIV-1
envelope vulnerability, providing vaccine designers
with new options.176 Immunity 38, 176–186, January 24, 2013 ª2013 Elsevier Inc.INTRODUCTION
Development of a safe and effective HIV-1 vaccine is a global
priority. After several failed efficacy trials, in 2009 the HIV-1 field
was encouraged by an estimated 31.2% vaccine efficacy in the
RV144 Thai HIV-1 vaccine efficacy trial that used a canarypox
virus vector (ALVAC) prime and a combination of clades B
and E gp120 (AIDSVAX gp120 B-E) proteins as a boost
(Rerks-Ngarmet al., 2009). This trial provided hope that a vaccine
could induce protective immune responses to HIV-1 (Rerks-
Ngarm et al., 2009). In 2012 an immune correlates study of
the RV144 trial revealed that antibodies against the Env gp120
V1-V2 region were associated with lower risk of infection
(Haynes et al., 2012a). Epitope mapping of plasma V1-V2 anti-
body responses showed that within V2, vaccine-induced anti-
bodies targeted a region of HIV-1 Env, amino acid (aa) residues
at positions 163–178 (Karasavvas et al., 2012; S. Zolla-Pazner
et al., 2011, AIDS Res. Hum. Retrovirus., abstract). There is
considerable sequence variability in V1-V2; 75% of the resi-
dues are conserved or demonstrated to be only conservative
changes (Zolla-Pazner and Cardozo, 2010). Although the
demonstration that V1-V2 antibody responses directly corre-
lated with decreased infection risk was suggestive of their
protective role in the trial, this association was not sufficient for
proving causation of protection (Plotkin and Gilbert, 2012).
Indeed, further studies are needed to evaluate the ability of
Figure 1. Binding of RV44 mAbs CH58 and CH59 to HIV-1-Infected Cells and to HIV-1 V2 Peptides
(A) Effect of alanine point substitutedmutations on the binding of CH58 (in blue) and CH59 (in red) to the HIV-1 V2 peptide. For eachmutation (y axis), results were
normalized as EC50 relative to wild-type V2 peptide.
(B) Shown is the flow cytometric analysis of binding of mAbs CH58 (top left), CH59 (middle left), and A32 (bottom left) to the activated PB CD4+ T cells infected
IMCCM235. Synagis (antirespiratory syncytial virus mAb) and mAb HIV-1 A32 were used as negative and positive controls, respectively. Mean fluorescence
intensity (MFI) and percent of positive cells are indicated next to the histograms. Data shown are representative of three independent experiments.
See also Figure S1 and Table S1.
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HIV-1 Vaccine Immune Correlate Antibodiessuch responses to mediate immune pressure on HIV-1. Viral
genetic (sieve) analyses, isolation of V1-V2 antibodies, and
understanding their effector function in vitro and in vivo, as well
as validation of correlates of infection risk in future vaccine trials
are needed.
By comparing sequences of breakthrough infections that oc-
cured in vaccinees versus placebo recipients, genetic or sieve
analysis of sequences of viruses that caused breakthrough
infections in a vaccine trial can demonstrate sites of immune
pressure (Rolland et al., 2011). A recent genetic analysis of
breakthrough HIV-1 infections in the RV144 trial demonstrated
48% (CI: 18% to 68%, p = 0.0036) vaccine efficacy against
viruses matching the CRF_01AE vaccine immunogens with
a lysine (K) at position 169 (Rolland et al., 2012). Thus, it is critical
to determine the binding site and effector functions of RV144-
induced V1-V2 antibodies. Antibody effector function candi-
dates for mediation of protection from HIV-1 transmission
include the ability of V1-V2 antibodies to neutralize those virus
strains involved in HIV-1 transmission (i.e., transmitted-founder
viruses) (Keele et al., 2008) or to mediate other effector functions
such as antibody-dependent cellular cytotoxicity (ADCC)
(Haynes et al., 2012a). Herein, we have probed the specificities
and effector functions of four V2 monoclonal antibodies (mAbs)
isolated from RV144 ALVAC-AIDSVAX vaccine recipients and
determined the crystal structures of two of these mAbs with V2
peptides containing position 169.We show that V2 residue 169 was in a structurally polymorphic
region of HIV-1, thus revealing the structural heterogeneity of the
V2 region to which Env immune responses correlated with
decreased transmission. We go on to show that the V2 anti-
bodies isolated from RV144 vaccinees mediated ADCC against
RV144 trial breakthrough Env-target cells, and this ADCC activity
was dependent on position 169 in breakthrough Envs. These
data directly demonstrate the plausibility of these types of V2
antibodies to mediate immune pressure targeted at position
169 of Env V2.
RESULTS
Vaccine-Induced Antibodies
With clonal memory B cell cultures and high-throughput antigen-
specific screening assays (Bonsignori et al., 2011), two mAbs,
CH58 and CH59, were initially isolated and found to bind the
RV144 vaccine immunogen AE.A244 gp120 and to a V2 peptide
(residues 169–182, KKKVHALFYKLDIV) (Table S1; Figure S1A
available online). Epitope mapping of mAbs CH58 and CH59
via alanine-scanning peptides with the sequence of AE.A244
Env from positions 165 to 186 (LRDKKQKVHALFYKLDIVPIED)
showed that the footprint for binding of mAb CH58 involved
ten residues (K168, K169, K171, V172, H173, F176, Y177,
K178, D180, P183), whereas that of mAb CH59 involved
four residues (K169, H173, F176, Y177) (Figure 1A). HIV-1 EnvImmunity 38, 176–186, January 24, 2013 ª2013 Elsevier Inc. 177
Figure 2. Binding of RV144 V2 and PG9 bnAbs to AE.A244 V1-V2 Tags Protein and AE.A244 D11gp120
Each of the mAbs was captured on a Fc antibody immobilized sensor surface to about 100–125 RU. For binding to A244 D11gp120, 2–10 mg/ml (CH58 in A),
2–10 mg/ml (CH59 in B), 10–50 mg/ml (PG9 in C) of monomeric gp120 were injected over each of the mAbs. AE.A244 V1-V2 tags protein was injected at
concentrations ranging from 0.5–5 mg/ml (CH58 in D), 0.1–5 mg/ml (CH59 in E), 10–100 mg/ml (PG9 in F). A negative control mAb (Synagis) was used to subtract
nonspecific binding. Each plot shows binding curves with increasing concentrations of gp120 or V1-V2 proteins (shown in different colors) injected over two
independent flow cells immobilized with the same mAbs. For binding to CH58 and CH59 mAbs, A244 D11gp120 protein was injected at 2, 4, 6, 8, and 10 mg/ml
and AE.A244 V1-V2 protein at 0.2, 0.5, 1, 2, 3, 4, and 5 mg/ml. For PG9 mAb, A244 D11gp120 and AE.A244 V1-V2 proteins were injected at 10, 20, 30, 40, and
50 mg/ml and 10, 25, 50, 75, and 100 mg/ml, respectively. Global curve fitting (shown in black) to a 1:1 Langmuir model was used to derive rate constants and Kd
values after simultaneous fitting to binding data from two independent flow cells with the samemAb captured. A third flow cell with each of the mAbs gave similar
rate constant values. See also Figure S2 and Table S2.
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HIV-1 Vaccine Immune Correlate AntibodiesV1-V2 broadly neutralizing antibodies (bnAbs) have been
described that bind both glycans as well as V1-V2 aa residues
around and including position 169 (Bonsignori et al., 2011;
Doria-Rose et al., 2012; McLellan et al., 2011; Walker et al.,
2009). The epitope mapping results suggested that mAbs
CH58 and CH59 (although themselves not bnAbs) bind at or
near the site in V2 to which the HIV-1 V1-V2 bnAbs (e.g., PG9,
CH01) bind (Doria-Rose et al., 2012; McLellan et al., 2011).
CH58 and CH59 bound to two Env immunogens used in
the ALVAC vCP1521-AIDSVAX B-E vaccine (AE.A244 and
AE.92TH023) (Table S1). Both antibodies bound to the surface
of CD4+ T cells infected with infectious molecular clone (IMC)
of tier 2 (Seaman et al., 2010) HIV-1 AE.CM235 and mediated
ADCC with CEM.NKRCCR5 cells as targets (Figure S1B). In178 Immunity 38, 176–186, January 24, 2013 ª2013 Elsevier Inc.surface plasmon resonance (SPR) assays, mAbs CH58, CH59,
and PG9 bound well to AE.A244 D11gp120 with Kds of 1.0 nM,
2.2 nM, and 42.1 nM, respectively (Figures 2A–2C and S2). Simi-
larly, CH58, CH59, and PG9 also bound well to AE.A244 V1-V2
tags protein with Kds of 0.12 nM, 0.48 nM, and 81.6 nM, respec-
tively (Figures 2D–2F and S1C). Binding kinetics of PG9 were
distinct from CH58 and CH59 in having slower association rates
(about 40-fold compared to AE.A244 V1-V2 tags and about 5- to
18-fold slower than AE.A244 D11gp120) (Figure 2). Thus, both
RV144 V2 mAbs CH58 and CH59 and V1-V2 bnAb PG9 bound
to recombinant HIV-1 Env proteins, A244 V1-V2 tags, and
AE.A244 D11gp120. HIV-1 gp120 has been demonstrated to
interact with the a4b7 molecule on CD4
+ T cells via a tripeptide
(LDI) motif in V2 (Arthos et al., 2008; Nawaz et al., 2011). Both
Table 1. Data Collection and Refinement Statistics
PDB ID
CH58 Fab
CH58 with V2
Peptide
CH59 with V2
Peptide
4HQQ 4HPO 4HPY
Data Collection
Space group P212121 C2 P212121
Cell dimensions
a, b, c (A˚) 63.0, 70.4,
135.8
140.6, 75.8,
54.7
41.9, 79.2,
127.1
a, b, g () 90.0, 90.0,
90.0
90.0, 112.0,
90.0
90.0, 90.0,
90.0
Resolution (A˚) 50.0–2.4
(2.44–2.40)a
50.0–1.7
(1.73–1.70)a
20.0–1.5
(1.53–1.50)a
Rsym or Rmerge (%) 13.6 (50.6) 9.6 (38.7) 11.8 (87.4)
I/sI 18.2 (2.0) 19.5 (1.9) 21.2 (3.7)
Completeness (%) 97.7 (82.8) 90.7 (56.1) 100 (100)
Redundancy 6.3 (3.3) 3.3 (2.2) 7.0 (5.6)
Refinement
Resolution (A˚) 25.8–2.40 24.8–1.69 19.9–1.50
No. reflections 23,681 53,364 68,657
Rwork/Rfree 0.183/0.225 0.185/0.211 0.171/0.187
No. atoms
Protein 3,232 3,413 3,344
Ligand/ion - 24 12
Water 191 403 521
B factors
Protein 52.8 42.1 16.5
Ligand/ion - 92.7 22.1
Water 49.1 42.4 32.1
Rmsds
Bond lengths (A˚) 0.004 0.007 0.004
Bond angles () 0.87 1.11 1.00
See also Figure S2.
aValues in parentheses are for highest-resolution shell.
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HIV-1 Vaccine Immune Correlate AntibodiesCH58 and CH59 mAbs inhibited interactions of V2 peptide with
a4b7 (Table S2). When assayed for ability to capture infectious
viruses, CH58 and CH59 captured infectious virions of
AE.92TH023 strain but not of HIV-1 AE.CM244 strain (Table
S2). Thus, a prime candidate for vaccine-induced protective
function is via antibody binding to virus-infected CD4+ T cells.
HIV-1 strains can be classified in tiers according to their rela-
tive ease or difficulty by which they are neutralized by Env anti-
bodies (Seaman et al., 2010). Tier 1 HIV-1 strains are laboratory
adapted and neutralization sensitive, whereas tier 2 HIV-1 strains
are from field isolates and are more difficult to neutralize; no
plasma tier 2 neutralizing activity was found in RV144 vaccinees
(Montefiori et al., 2012). Both CH58 and CH59 mAbs neutralized
the tier 1 virus pseudotyped with AE.92TH023 Env that was
included in ALVAC as prime vaccine immunogen (Table S3;
Rerks-Ngarm et al., 2009). Neutralization of AE.92TH023 by
both antibodies was abrogated when a K169Q mutation was
introduced in the virus envelope (Table S3). mAbs CH58 and
CH59 also neutralized the tier 1 clade C SHIV1157ipEL-p, but
not the tier 1 B.MN or the tier 2 AE.CM244 strains that comprised
the gp120 components in AIDSVAX vaccine, nor did they
neutralize other tier 1 or 2 HIV-1 strains tested (Table S3).
Although both the tier 2 AE.CM244 and tier 1 AE.92TH023
HIV-1 strains have identical V1-V2 sequences spanning residues
165–184 that contain the CH58 and CH59 epitopes, mAbs CH58
and CH59 neutralized only HIV-1 tier 1 strain, AE.92TH023.
The differential neutralization of tier 1 AE.92TH023 but not
tier 2 AE.CM244 can be explained by the failure of CH58 and
CH59 to capture tier 2 AE.CM244 infectious virions, although
both antibodies can capture tier 1 AE.92TH023 infectious virions
(Table S2). Thus, neutralization of HIV-1 is not a likely candidate
for protective effector function of vaccine-induced antibodies.
Because bnAbs that target V1-V2 regions (Bonsignori
et al., 2011; Walker et al., 2009) (e.g., PG9, PG16, and CH01)
and V2 conformational mAbs (e.g., 697D) (Gorny et al., 2012)
that also target epitopes in V2 are glycan dependent, we next
used peptides, recombinant gp120, and V1-V2 constructs to
determine the dependence of CH58 and CH59 binding on
adjacent N160, N156 glycan sites. Whereas 697D, PG9, PG16,
and CH01 did not bind to linear and cyclic V2 peptides (not
shown), both CH58 and CH59 bound well to V2 peptide
(KKKVHALFYKLDIV) with EC50 of 0.06 mg/ml and 0.003 mg/ml,
respectively (Figure S1A). Thus, the binding of CH58 and CH59
to V2 is glycan independent.
We have previously described that bnAbs PG9, PG16, and
CH01 bound well to recombinant HIV-1 Env AE.A244 gp120
(Bonsignori et al., 2011). We constructed N160K mutants of
AE.A244 gp120 and found that whereas the binding of bnAbs
PG9, PG16, and CH01 to AE.A244 gp120 was abrogated by
the N160K mutation, the binding of CH58 and CH59 mAbs was
not (Table S1). In addition, native deglycosylation (Ma et al.,
2011) (that removes a subset of glycans) of the AE.A244 V1-V2
tags protein (Figure S1C) abrogated the binding of V1-V2 bnAbs
CH01, PG9, and PG16 and decreased the binding of mAb 697D
6-fold but did not affect CH58 and CH59 Env binding (Table S1).
Similarly, the N156Q, N160Q mutations had no effect on CH58
and CH59 binding to A244 V1-V2 tags protein, whereas the
two mutations completely abrogated the binding of bnAbs
PG9, PG16, and CH01 and markedly decreased the binding bymAb 697D, thus confirming the glycan independence of CH58
and CH59 V1-V2 binding (Figure S1D).
Crystal Structures of Vaccine-Induced Antibodies
and HIV-1 Env
We determined a crystal structure of the CH58 antigen-binding
fragment (Fab) alone, but several residues in the third comple-
mentarity-determining region of the heavy chain (CDRH3) were
disordered (Figure S3A). We next determined crystal structures
of the CH58 or CH59 Fabs in complex with an AE.92TH023
Env V2 peptide 164-ELRDKKQKVHALFYKLDIV-182 to 1.7 A˚
and 1.5 A˚, respectively. The CH58:peptide structure was refined
to an Rcryst/Rfree of 0.185/0.211 (Table 1) and revealed that CH58
recognizes V2 residues 167–176 as an a helix and residues 177–
181 as an extended coil (Figure 3A). Surprisingly, the CH59:pep-
tide structure, which was refined to an Rcryst/Rfree of 0.171/0.187
(Table 1), revealed that CH59 recognizes residues 168–173 as
coil or turn and residues 174–176 as a short 310 helix (Figure 3B).
Thus, the two Fabs recognize similar V2 residues in completely
different conformations. In general, the interactions observedImmunity 38, 176–186, January 24, 2013 ª2013 Elsevier Inc. 179
Figure 3. Structures of Antibodies CH58 and CH59 Bound to an HIV-1 gp120 V2 Peptide
Vaccine-elicited antibodies CH58 and CH59 recognize alternative conformations of V2 compared to bnAb PG9.
(A) Top: Ribbon representation of the CH58 antigen-binding fragment in complex with an A244 V2 peptide. Heavy chain is colored orange, light chain is blue, and
peptide is green. The sequence of the peptide is shown, with modeled residues in green. Bottom: Close-up of the top panel rotated 90 about a horizontal axis.
The side chains of residues involved in hydrogen bonds or salt bridges are shown as sticks, with the interactions depicted as dashed lines.
(B) Structure of CH59 in complex with peptide, depicted as in (A). The heavy chain is tan, and the light chain is light blue.
(C) Structure of bnAb PG9 in complex with the V1-V2 domain from HIV-1 strain CAP45 (PDB ID: 3U4E) (McLellan et al., 2011). The PG9 structure is shown as
ribbons with heavy and light chains (colored yellow and blue, respectively) in the same orientation as in (A) and (B). The V1-V2 domain is shown as a gray ribbon
with residues 168–176 colored green and N-linked glycans attached to residues Asn156 and Asn160 shown as sticks.
See also Figure S3 and Table S3.
Immunity
HIV-1 Vaccine Immune Correlate Antibodiesin the crystal structures agreed well with the peptide-mapping
studies, and both Fabs made multiple hydrogen bond or salt
bridge interactions with K169 and H173. Collectively, these
results demonstrate antibody binding sites for both mAbs
CH58 and CH59 at the position of imputed immune pressure
(K169) induced by ALVAC-AIDSVAX B-E vaccination (Rolland
et al., 2012).180 Immunity 38, 176–186, January 24, 2013 ª2013 Elsevier Inc.CH58 and CH59 mAb binding sites also involved residues that
are components of the bnAb PG9 binding site (Figure 3C; Doria-
Rose et al., 2012; McLellan et al., 2011). In addition to binding to
aa within 168–178 of a scaffolded-V1-V2 recombinant protein,
mAb PG9 binds to N-linked glycans at N160 and N156 (Pancera
et al., 2010; Walker et al., 2009). PG9 also recognizes positively
charged V2 residues with a combination of sulfated tyrosines
Table 2. Effect of Amino Acid Substitutions in the V2 Region of HIV-1 Env on Ability of HIV-1 V2 mAbs to Bind
mAb
EC50, mg/ml
A244 gp120 AE.703359 gp120 AE.427299 gp120 gp70 B.CaseA2 V1-V2
WT K169V Mut3 WT Q169K Mut3 WT Q169K Mut4 WT V169K Mut3
RV144V2 Antibodies
CH58 0.03 0.05 7 0.38 0.04 0.07 22.5 3.4 0.03 1.2 0.025 0.03
CH59 0.029 0.58 NB NB 1.2 0.05 NB NB 0.03 NB NB 0.02
Other V1V2 Antibodies
697D 0.1 0.06 0.08 0.21 0.51 0.12 0.07 0.13 NB 0.04 0.14 0.04
PG9 0.6 3 >100 >5 0.53 0.54 0.47 0.13 >10 NB >100 >10
PG16 >10 >100 NB NB >10 >10 >10 0.26 NB NB NB NB
CH01 0.35 0.13 0.93 NB NB NB >10 >10 NB NB NB NB
The indicated HIV-1 Env wild-type (WT) and Env mutants with a single aa residue substitution at the position 169, 3 aa residue substitutions (Mut3), or
4 aa residue substitutions (Mut4) were assayed in ELISA. See also Table S4.
AE.A244 gp120/Mut 3 = K169V/V172E/H173Y.
AE.703359 gp120/Mut 3 = Q169K/R170Q/Q173H.
AE.427299 gp120 /Mut 4 = R168K/Q169K//Y173H/A174V.
gp70 B.CaseA2 V1-V2 /Mut3 = V169K/E172V/E173H.
Immunity
HIV-1 Vaccine Immune Correlate Antibodiesand acidic residues. mAbs CH58 and CH59, however, demon-
strated no tyrosine sulfation (Figure S3B).
The crystal structures of CH58, CH59, and PG9 antibodies in
complex with their epitopes reveal substantial differences in
the conformations of V2 residues 168–176. These residues are
bound to CH58 as an a helix, to CH59 as a coil and 310 helix,
and to PG9 as a b strand (Figure 3; McLellan et al., 2011).
Whereas PG9 is a bnAb for tier 2 HIV-1 strains, PG9 and the
related PG16 and CH01-CH04 bnAbs do not neutralize most
tier 1 HIV-1 strains (Bonsignori et al., 2011; Pancera et al.,
2010; Walker et al., 2009). Conversely, CH58 and CH59
neutralize only select tier 1 HIV-1 and no tier 2 strains. That
PG9 binds to V1-V2 in a b strand conformation whereas CH58
and CH59 recognize alternative V2 conformations raises several
hypotheses. First, this V1-V2 region may exist in multiple confor-
mations because CH58, CH59, and PG9 all bind to AE.A244
gp120 and V1-V2 tags proteins (Figures 2A–2F; Table S1)
despite their binding to different conformations in their respec-
tive crystal structures. Alternatively, the predominant conforma-
tion of V1-V2 on peptides and recombinant Env constructs may
be different from that on virion trimeric Env and on virus-infected
CD4+ T cells. Third, the conformation of V2 aa 168–176 may take
on alternate conformations in tier 1 versus tier 2 HIV-1 strains on
virions and virus-infected cells.
Reactivity of RV144 Vaccinee Plasma with RV144
Vaccine Envs, RV144 Placebo Infection Breakthrough
AE.Envs, and gp70V1-V2 Case A2 Fusion Protein
Mutants
An immune correlates study of RV144 vaccinees demonstrated
that antibodies to a gp70V1-V2 fusion protein (gp70V1-V2
CaseA2) correlated with lowered infection risk (Haynes et al.,
2012a). Whereas in the RV144 sieve analysis, vaccine efficacy
was 48% (p = 0.0036, 95% CI:18%, 66%) against viruses that
matched the vaccine at V2 aa169K (Rolland et al., 2012), the
gp70V1-V2 CaseA2 protein has a valine at aa 169, and of
CH58 and CH59, only CH58 binds to gp70V1-V2 CaseA2 fusion
protein. Thus, there are two distinct but related antibody corre-lates of risk of infection identified in the RV144 trial that are rele-
vant to CH58 and CH59 antibodies in this paper: (1) antibodies
that bind to gp70V1-V2 CaseA2 scaffold (e.g., CH58-like anti-
bodies) and (2) antibodies that bind to K169 and can potentially
mediate immune pressure as found in the RV144 sieve analysis
(e.g., CH58- and CH59-like antibodies).
We next determinedwhether CH58, CH59, and other V2mAbs
including conformational V2 mAb 607D and bnAbs CH01, PG9,
and PG16 reacted with the vaccine Env A244 wild-type (WT),
RV144 placebo (i.e., breakthrough) infection Envs (that did not
match vaccine Envs), and gp70V1-V2 CaseA2 scaffold WT
(V169), and evaluated the effect of mutations introduced in the
CH58 and CH59 footprints (Table 2).
We found that CH58 and CH59 binding was high on WT
A244 gp120 and either reduced for CH58 or abrogated for
CH59 on A244 gp120 with K169V, V172E, and H173Y muta-
tions (mutations away from the sequence of the vaccine
Envs) (Table 2). For Envs 703357 and 427299 gp120s derived
from RV144 placebo breakthrough infection (that did not match
the vaccine in V2), binding of CH58 was low on WT and
increased by two logs on R168K, Q169K, Y173H, A174V Env
mutants (mutations that changed the breakthrough infection
Env sequences to match those of the Env vaccines). Similarly,
CH59 did not bind to WT breakthrough infection Envs but did
bind well to breakthrough Envs with Q169K, R170Q, and
Q173H mutations (Table 2). Finally, although CH58 but not
CH59 bound to gp70V1-V2 CaseA2 fusion protein, the intro-
duction of V169K, E172V, and E173H substitutions (to match
the vaccine Envs) within the CH58 and CH59 footprints on
the V1-V2 fusion protein resulted in increased binding of
CH58 and the appearance of CH59 binding (Table 2). The V2
conformational mAb 697D and V1-V2 bnAbs CH01, PG9, and
PG16 had either little or varying binding patterns to these
Envs and their mutants (Table 2). The evidence that the same
mutations to whole gp120 proteins and V2 peptides similarly
abrogated the binding of mAbs CH58 and CH59 lends to, but
does not prove, the relevance of the structures obtained with
V2 peptides.Immunity 38, 176–186, January 24, 2013 ª2013 Elsevier Inc. 181
Table 3. Binding of Recombinant HIV-1 Envs and Select V1-V2 Recombinant Constructs by Mature Mutated RV144 V2, V2-V3 bnAbs,
and V2 Conformational mAb and Their Reverted Unmutated Ancestor Antibodies in ELISA
HIV-1 Env
EC50, nM
CH58 CH59 CH01 697D PG9 PG16 CH58 UA CH59 UA CH01 UA3 697D UA PG9 UA PG16 UA
AE. A244 V1-V2 tagsa 0.02 0.014 8.9 0.1 1.1 3.7 4.9 0.13 18 NB NB NB
AE.A244 D11gp120a 0.07 0.087 0.47 0.23 0.53 37.6 >667 15.5 9.3 >667 NB NB
A.Q23V1-V2 tagsa >66.7 NB >66.7 >66.7 14.94 >66.7 NB NB NB >667 NB NB
B.6240 gp140Ca NB NB >667 0.016 0.3 10.3 NB NB NB 0.19 NB NB
gp70 B.CaseA2 V1-V2 9.3 NB NB 0.08 NB NB NB NB NB >667 NB NB
gp70 C.1086V1-V2 0.05 0.067 NB 0.067 NB NB >66.7 11.3 NB NB NB NB
C.1086V1-V2 tagsa 0.08 0.1 NB 0.23 >667 NB >667 50.1 NB NB NB NB
C.1086C D7gp120a 0.055 0.07 NB 0.02 NB NB >667 66.7 NB NB NB NB
Positive results in ELISA with EC50 above the highest tested concentration (100 mg/ml) are indicated as >667 nM; NB, no detectable binding. See also
Figure S5 and Table S4.
aAE., B., and C. represent the CRF or clades of HIV-1 Env.
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nees to these Env proteins and their mutants (Figure S4A). Anti-
body binding decreased significantly on A244 gp120 K169V
compared to WT A244 gp120 (p < 0.0001, paired Student’s
t test) and decreased further with the K169V, V172E, and
H173Y (Mut3) mutant of A244. For RV144 breakthrough Envs
AE.703359 and AE.427299, binding was significantly less on
WT Env than on the Envs containing mutations necessary for
optimal CH58 and CH59 binding (AE703359 mut3 and
AE427299 mut4) (p < 0.0001 for both Envs, paired Student’s t
test). Moreover, RV144 plasma antibodies bound AE.427299
Q169K Env significantly better than WT (p < 0.0001, paired
Student’s t test).
RV144 plasma antibodies bound to gp70V1-V2 B.CaseA2
protein (Figure S4A), with no significant improvement in binding
to the V169K mutant scaffold but dramatically improved
vaccinee plasma binding to the gp70V1-V2 B.CaseA2 protein
with 169K, E172V, and E173H triple mutations (p < 0.0001,
paired Student’s t test). Thus, the RV144 vaccine clearly induced
antibodies dependent on the CH58 and CH59 footprint aa resi-
dues found in the vaccine and used this footprint for recognition
of vaccine immunogen Env A244 gp120, and most importantly,
for recognition of breakthrough CRF_AE01 infection Envs with
CH58 and CH59 footprint mutations.
Reactivity of Unmutated Ancestor Antibodies of RV144
V2 mAbs and PG9, PG16, and CH01 V1-V2 bnAbs
The presence of multiple tyrosines in HCDR3s of CH58, CH01,
and PG9 and their unmutated ancestor antibodies (UAs) (Fig-
ure S3C) led us to suspect that reactivity of UAs of RV144 V2
mAbs and these bnAbs may be similar. We constructed reverted
UAs as models for naive B cell receptors for CH58, CH59, PG9-
PG16, CH01-CH04, and 697D and compared their reactivity to
43 recombinant Envs or V1-V2 scaffold constructs (Tables 3
and S4; Figures S5A–S5N). We found that whereas the mature
CH58 and CH59 antibodies reacted with 26 of 43 and 15 of 43
of the Env constructs, respectively, their UAs reacted with only
5 of 43 (Figures S5A–S5D). Remarkably, although CH58 and
CH59 are from different VH families, their UAs reacted with the
same Env constructs (AE.A244 D11gp120, AE.A244 V1-V2182 Immunity 38, 176–186, January 24, 2013 ª2013 Elsevier Inc.tags, C.1086 D7gp120, C.1086 gp70 V1-V2 scaffold, and
C.1086 V1-V2 tags proteins).
Finally, two of three of the Env constructs that reacted with the
UAs of CH58 and CH59 (AE.A244 D11gp120, AE.A244 V1-V2
tags) also reacted with the UAs of the CH01-CH04 V1-V2 bnAb
clonal lineage (Table 3; Figures S1E and S5E–S5H). In contrast,
none of the 43 Envs tested reacted with UAs of PG9 (Figures S5I
and S5J) or PG16 (Table 3; Figures S5K and S5L) and the Env
constructs that reacted with the UA of 697D were entirely
different than those reacting with the UAs of any of the other
mAbs studied (Figures S5M and S5N).
CH58-like and CH59-like Antibodies in RV144 Vaccinee
Plasma
To determine the titers of CH58- and CH59-like antibodies
present in RV144 vaccinee plasma, we established assays
wherein we tested vaccinee plasma for the ability to block
the binding of biotinylated CH58 or CH59 to AE.A244 gp120
Env protein. We found that vaccinee plasma had a mean
of 3.2 mg/ml (range 0–13.9 mg/ml) of CH58-like antibody and
2.5 mg/ml (range 0–11.7 mg/ml) of CH59-like antibody (Fig-
ure S4B). Thus, 12 of 43 (28%) of RV144 vaccinees studied
had >5.0 mg/ml of either CH58- or CH59-like plasma antibody
levels, and the ranges of induced V2 antibodies was within the
levels required for RV144 V2 mAb-mediated ADCC and tier 1
neutralizing activity.
CH58 and CH59 mAbs were derived from the same RV144
vaccinee (347759). To determine the presence of K169 mAbs
in other vaccinees, we studied two additional subjects (200184
and 302689) and were able to isolate two additional V2 anti-
bodies (HG107, HG120) with footprints nearly identical to
CH59 (Figure S6, Table S5). Moreover, these two V2 antibodies
both neutralized AE.92TH023 HIV-1 (Table S3) and mediated
ADCC of tier 2 AE.CM235-infected CD4 CEM.NKRCCR5 T cells
(Figure 4). Importantly, when the A244 gp120 and RV144 break-
through infection 427299 and 703357 Env gp120s were used to
coat CD4 CEM.NKRCCR5 T cell targets in ADCC assays, the
ability of CH58, CH59, HG107, and HG120 mAbs to mediate
ADCC was dependent on CH58, CH58, HG107, HG120 mAb
footprint mutations that included 169K (Figure 4).
Figure 4. Effect of V2 mAbs CH58, CH59,
HG107, HG120 Footprint Mutations in
HIV-1 Vaccine AE.A244 Env and RV144
Breakthrough AE.427299 and AE.703357
Envs onAbility of V2mAbs toMediate ADCC
Panels show the ability of mAb A32 and RV144 V2
mAbs CH58, CH59, HG107, HG120 to mediate
ADCC against gp120-coated CD4 cell (CEMCCR5)
target T cells. Data shown are maximum percent
granzyme B activity from ADCC. Top panel shows
that CH58, CH59, HG107, and HG120 mAbs all
mediate high levels of ADCC against WT AE.244
Env-coated CD4 T cell targets (white bars), and
this killing is mitigated by a single K169V mutation
(gray bars) and is abrogated by the full V2 mAb
footprint set of mutations (black bars). Middle
and lower panels show, in contrast, that none of
the CH58, CH59, HG107, and HG120 mAbs
mediated ADCC against RV144 breakthrough Env
AE.427299 and AE.703357 WT CD4 T cell targets
(with V2s that did not match the RV144 vaccine)
(white bars), and that ADCC was restored mini-
mally with AE.703357 targets with the Q169K
mutation (gray bars), and restored in a pronounced
manner in both breakthrough Env targets with the
full set of mutations that include Q169K that
restored the V2 mAb footprint mutations (black
bars). Purified NK cells isolated from a normal
donor with Fc-gamma receptor IIIa FF phenotype
were used as effector cells. The effector to target
ratio was 10:1. Error bars showmean ± SEM. Each
antibody was tested in a wide dose curve starting
at 40 mg/ml with 4-fold dilutions. See also Figures
S4 and S6 and Table S5.
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were Vl3-10 with a common aa glutamate-aspartate (ED)
residuemotif in LCDR2 that is critical for binding to K169 (Figures
S6A–S6C), in that the D of this motif in CH59 forms a salt bridge
with V2 K169 (Figures 3, S6G, and S6H). In CH58, the Ig light
chain is Vl 6-57 and also shares the LCDR2 ED motif (Fig-
ure S6C), with the E of the motif binding K169 in the V2-CH58
structure (Figures S6G and S6H). Overlayed LCDR2 ED motif
regions of CH58 and CH59 show striking similarity between the
two LC-Env binding regions (Figures S6G and S6H). Thus, with
four V2 antibodies from three different RV144 vaccinees, light
chain usage was restricted to Vl light chains containing an
LCDR2 ED motif required for CH58 and CH59 Env V2 K169
binding.
DISCUSSION
89%of infections in the RV144 efficacy trial were with CRF01_AE
HIV-1 strains (Rerks-Ngarm et al., 2009). One correlate of infec-
tion risk from the RV144 trial analysis is the genetic analysis of
Env sequences in vaccine compared to placebo recipients that
demonstrated increased vaccine efficacy against viruses with
a V2 K169 residue among vaccines (Rolland et al., 2012). This
signature at K169 suggested the hypothesis that RV144 V2 anti-
bodies such as CH58 and CH59 may have mediated, in as yet
undefinedmanners, immune pressure at that site. Based on anti-
body effector functions shown to be mediated in vitro by mAbs
CH58, CH59, HG107, and HG120, the potential mechanisms ofantibody-mediated immune pressure include (1) virus neutraliza-
tion of susceptible CRF01_AE HIV-1 strains and (2) binding
HIV-1-infected CD4 T cells and mediation of ADCC, or other as
yet undefined effector mechanisms.
A second immune correlate of lowered infection risk is the anti-
body response to V1-V2 asmeasured by the clade B gp70 V1-V2
CaseA2 fusion protein (Haynes et al., 2012a). Because gp70 V1-
V2 CaseA2 has a V169 and only CH58 binds to this protein, there
may be at least two types of RV144 V2 antibodies capable of
mediating immune pressure: those that bind to gp70 V1-V2
CaseA2 protein and bind K169 (i.e., CH58-like), and those that
do not bind to gp70 V1-V2 CaseA2 protein and bind K169 (i.e.,
CH59, HG107, HG120-like). Critical studies going forward will
be to perform new efficacy trials in humans and perform passive
protection trials in rhesus macaques with RV144 V2 antibodies
with R5 SHIVs derived from RV144 trial breakthrough infections
to directly explore the protective effect of these two types of V2
mAbs. Nonetheless, the studies in the present report describe
two types of V2 antibodies induced by the RV144 vaccine that
recognize K169, define their structures and effector function
capabilities, and demonstrate light chain conserved usage for
binding to the Env V2 K169 site of immune pressure.
A key task for the HIV-1 vaccine development field is to
improve the degree of vaccine efficacy seen in the RV144 clinical
trial with subsequent vaccine designs. Vaccine designers gener-
ally focus on regions of conservation. For RNA viruses such as
influenza and HIV-1, which are highly divergent and capable of
rapid genetic alteration, conserved regions on Env are generallyImmunity 38, 176–186, January 24, 2013 ª2013 Elsevier Inc. 183
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regions that may be more susceptible to antibody-mediated
neutralization. Indeed, antibodies directed against the variable
head region of influenza hemagglutinin are the source of the
vaccine protection elicited by the seasonal influenza vaccines
(Karlsson Hedestam et al., 2008). With the RV144 trial, it also
seems a variable region—in this case, around residue 169 of
V2—is the site of successful vaccine-induced immune pressure.
Virologically, it makes sense that selection and/or immune pres-
sure could be identified by variation. Our results with RV144 trial
antibodies CH58, CH59, HG107, and HG120 mAbs indicate
that this variation may include not only sequence diversity but
also conformational changes in the structure of the same aa
sequence. Despite extraordinary variation in both sequence
and structure, the humoral immune system appears capable of
recognizing V1-V2 in the setting of vaccination with a restricted
Ig light chain LCDR2 motif, and Env immunogens that focus
the elicited response to this V2 region should be explored.
EXPERIMENTAL PROCEDURES
Plasma and Cellular Samples from Vaccine Recipients
Forty plasma samples and three peripheral blood mononuclear cell (PBMC)
samples (347759, 200134, and 302689) were obtained from vaccine recipients
enrolled in the RV144 phase III efficacy trial as described (Rerks-Ngarm et al.,
2009). All work related to human subjects was in compliance with Institutional
Review Board protocols approved by the Duke University Health System Insti-
tutional Review Board.
Production of Recombinant Antibodies
Three RV144 vaccine recipients (347759, 200134, and 302689) were studied
for isolation of HIV-1 antibodies (Figure S3C). mAbs CH58 and CH59 from
RV144 vaccine recipient 347759 and mAb HG107 from RV144 vaccine recip-
ient 200134 were isolated by screening clonal cultures of memory B cells with
either AE.A244 gp120 (for CH58 and CH59) or A244 V1-V2 (for CH107) tags
followed by isolation of VH and VL genes as described (Bonsignori et al.,
2011; Liao et al., 2009, 2011). mAb HG120 was isolated from RV144 vaccine
recipient 302689 by flow sorting HIV-1 V2-specific single memory B cells
cultured overnight (Bonsignori et al., 2011) via dual color fluorochrome-labeled
AE.A244 V1-V2 tags followed by isolation of VH and VL genes as described
(Bonsignori et al., 2011; Moody et al., 2012). In the memory B cell culture
system used to isolate CH58 and CH59 (Bonsignori et al., 2011), of 5,232
IgG+ memory B cell cultures, 5 cultures were scored as positive for V2 reac-
tivity in the initial culture screen. This yielded a frequency of V2-reactive
memory B cells of 0.096%, a frequency comparable to the frequency of immu-
nodominant V3 antibody-producing B cells (0.13%) induced in the VAX004 HIV
vaccine clinical trial (Bonsignori et al., 2009).
VH and VL genes of 697D (Gorny et al., 1994) were obtained from M. Gorny
and S.Z.-P. (New York University, NY). V1-V2 bnAbs PG9 and PG16 (Walker
et al., 2009) were provided by D. Burton (Scripps Institute, La Jolla, CA).
mAbs 7B2 and A32 were provided by J. Robinson (Tulane University, LA),
and Synagis (MedImmune, LLC; Gaithersburg, MD), a human antirespiratory
syncytial virus mAb, was used as negative controls.
The reverted unmutated ancestor antibodies of CH58, CH59, CH01, 697D,
PG9, and PG16 were inferred and produced as described (Bonsignori et al.,
2011; Haynes et al., 2012b; Liao et al., 2011; Ma et al., 2011).
Production of Recombinant HIV-1 Proteins
Sequences of all HIV-1 Env proteins used in the study were summarized in
Table S4. RV144 vaccine proteins AE.A244 gp120, and B.MN gp120 were
supplied by GSID (Global Solutions for Infectious Diseases, South San
Francisco, CA) or produced as described (Alam et al., 2012; Liao et al.,
2006), HIV-1 Env A.92RW020, B.HXB/BAL, and C.97ZA012 were scaffolded
on J08 protein or murine leukemia virus (MLV) gp70 protein and produced
as fusion proteins as described (McLellan et al., 2011; Pinter et al., 1998).184 Immunity 38, 176–186, January 24, 2013 ª2013 Elsevier Inc.MLV gp70 carrier protein without V1-V2 sequence was similarly produced
and used as negative control. AE.703357 and AE.427299 Env gp160
sequences were obtained from RV144 subjects (placebo arm) and repre-
sented breakthrough infection Envs with V2 sequences that do not match
the RV144 AE vaccine strains A244 and 92TH023 and used to produce
recombinant gp120 proteins and gp120 mutants to match the V2 sequences
of RV144 vaccine AE strains, AE.A244 and AE.92TH023. HIV-1 Env V1-V2
tags proteins were designed with Ig leader (METDTLLLWVLLLWVPGSTGD)
serving as a mature protein cleavage and secretion signal at the N terminus
and with the C-terminal avi-tag followed by His6-tag for purification, produced
in 293F cells by transfection and purified by nickel columns. Other recombi-
nant HIV-1 Envs and Env mutants used in the study were produced as
described (Liao et al., 2006; Ma et al., 2011).
HIV-1 Env V2 Peptides
HIV-1 AE.A244 gp120 and AE.A244 V2-171 peptide (LRDKKQKVHALFYKLDI
VPIED) spanning from L165 to D186 and its 22 derivative alanine-scanning
peptides (Table S4) were produced (CPC Scientific Inc., San Jose, CA) for
epitope mapping of V2 mAbs.
SPR Kinetics Measurements
Binding Kd and rate constant measurements of mAbs to AE.A244 gp120 and
AE.A244 V1-V2 tags were carried out on BIAcore 3000 instruments as
described (Alam et al., 2007, 2008, 2011). All data analysis was performed
with the BIAevaluation 4.1 analysis software (GE Healthcare).
Determination of CH58-like and CH59-like Antibodies in Plasma
The levels of CH58-like and CH59-like antibodies in RV144 vaccinee plasma
(n = 40) were determined by blocking of the biotinylated mAbs CH58 and
CH59 to recombinant AE.A244 gp120 protein by serial dilutions of plasma of
the RV144 vaccinees (Alam et al., 2008).
Analysis of Binding of mAbs to HIV-1-Infected Cells
Analysis PB CD4+ T cells infected with replication-competent IMC (Edmonds
et al., 2010) was performed as described (Ferrari et al., 2011; Pollara et al.,
2011) except with a 2 hr incubation with primary antibody.
ADCC Assays
Assays for determining ADCC activity mediated by RV144 mAbs were carried
by luciferase ADCC assay and ADCC-GTL assay (Bonsignori et al., 2012;
Pollara et al., 2011; Trkola et al., 1999) by the methods as reported and
described in detail in Supplemental Experimental Procedures.
HIV-1 Virion Capture Assays
The ability of mAbs CH58 and CH59 to capture HIV-1 virions was tested by
HIV-1 p24 assay by the methods as described (Burrer et al., 2005) and to
capture infectious virions of HIV-1 92TH023 or CM244 was performed as
described (Leaman et al., 2010; Liu et al., 2011). In brief, the virus particles
or infectious virions in the uncaptured and captured fraction were measured
by viral RNA with HIV-1 gag real-time RT-PCR or TZM-bl infectious virus
capture readout, respectively. The captured RNA represents the viral RNA
(rVirion) after subtracting the background value (virus only). The percentage
of captured infectious virion (iVirion) was calculated as 100  the uncaptured
virus infectivity/virus only infectivity 3 100%.
Neutralization Assays
Neutralizing activity of mAbs were assayed in TZM-bl cell-based (Seaman
et al., 2010; Montefiori, 2005) and/or A33R cell-based (Montefiori et al.,
2012) neutralization assays.
Crystallographic Analysis of CH58 and CH59
CH58 and CH59 Fab preparation, crystallization, and data collection are
described in Supplemental Experimental Procedures. All diffraction data
were processed with the HKL2000 suite (Otwinowski and Minor, 1997), and
model building and refinement were performed in COOT (Emsley and Cowtan,
2004) and PHENIX (Adams et al., 2002), respectively. Automatic model
building was performed by Arp/wArp (Langer et al., 2008). Structure
Immunity
HIV-1 Vaccine Immune Correlate Antibodiesdetermination, model building, and refinement are described in Supplemental
Experimental Procedures.
Molecular Modeling
Homology models of the light chains for HG107 and HG120 were constructed
with ROSETTA 3.3’s threading protocol (Leaver-Fay et al., 2011) with the light
chain of CH59 from the crystal structure of the V2-CH59 complex as the
template. Themodel with the best energy score was selected from 100models
generated for each light chain.
ACCESSION NUMBERS
The GenBank accession numbers for VH and VL sequences of CH58, CH59,
HG107, and HG120 as well as CH58_UA, CH59_UA, 697D_UA, CH01_UA,
PG9_UA, and PG16_UA reported in this paper are KC417393 to KC417414.
Coordinates and structure factors for unbound CH58 Fab as well as CH58
and CH59 Fabs in complex with a V2 peptide have been deposited with
the Protein Data Bank under accession codes 4HQQ, 4HPO, and 4HPY,
respectively.
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